Stereotactic body radiotherapy for lung metastases from colorectal cancer: a single institution experience
Abstract
Aim: Stereotactic body radiotherapy (SBRT) has been used as an alternative to surgical intervention to treat primary malignanices of the lung as well as lesions from other primaries. In this study, we evaluate the safety and efficacy of SBRT in treating lung metastases from colorectal cancer (CRC). Materials & methods: We reviewed 22 patients that underwent lung SBRT for metastases from CRC. Almost all patients received chemotherapy before and after undergoing SBRT. Outcomes that were analyzed included overall survival, distant failure and progression-free survival, as well as the effects of biologically effective dose (BED) and KRAS status on local control. Results: Seven females and 15 males underwent SBRT to lung metastases from CRC. The median Eastern Cooperative Oncology Group status was one (0–2). The median dose was 48 Gy (40–54 Gy) in 5 fx (4–8 fx) and the median number of nodules treated with SBRT was one (1–3). Median follow-up was 28.5 months from SBRT and 79 months (9–145) from primary diagnosis. Local control at 1 and 3 years was 75 and 58%, respectively. There was a trend toward improved local control with increasing biologically effective dose (BED10 > 100; p = 0.07). Cancers that were positive for the KRAS mutation had increased local control at 12 months, 100 versus 75% (p = 0.0199). Median OS from the primary diagnosis of CRC and from SBRT was 79 and 31 months, respectively. There were no predictors for OS. There were no episodes of acute or late grade 3 or higher toxicity. Conclusion: The results of this study add to the growing body of literature to support SBRT for lung metastases, specifically those patients with limited lung metastases from CRC. The choice of radiation dose remains important, even in metastatic disease, as highlighted by the trend toward improved local control with increasing BED10.
References
- 1 . Cancer statistics, 2018. CA Cancer J. Clin. 68(1), 7–30 (2018).
- 2 . Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann. Surg. 240(3), 438–447; discussion 47–50 (2004).
- 3 Surgical outcome and prognostic stratification for pulmonary metastasis from colorectal cancer. Ann. Thorac. Surg. 104(3), 979–987 (2017).
- 4 . Pulmonary metastasectomy for colorectal cancer: how many nodules, how many times? World J. Gastroenterol. 20(20), 6133–6145 (2014).
- 5 Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J. Clin. Oncol. 27(20), 3290–3296 (2009).
- 6 Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 303(11), 1070–1076 (2010).
- 7 . Lung metastases treated with stereotactic ablative radiation therapy in oligometastatic colorectal cancer patients: outcomes and prognostic factors after long-term follow-up. Clin. Colorectal Cancer 16(1), 58–64 (2017).
- 8 . Stereotactic body radiotherapy for colorectal lung oligometastases: preliminary single-institution results. J. BUON 20(1), 158–165 (2015).
- 9 Exploratory analysis on overall survival after either surgery or stereotactic radiotherapy for lung oligometastases from colorectal cancer. Clin. Oncol. (R. Coll. Radiol.) 28(8), 505–512 (2016).
- 10 Stereotactic body radiotherapy for lung metastases from colorectal cancer: prognostic factors for disease control and survival. Am. J. Clin. Oncol. 41(1), 53–58 (2018).
- 11 Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases – A pooled analysis of the German working group “stereotactic radiotherapy”. Lung Cancer 97, 51–58 (2016).
- 12 . Regression models and life- tables. J. Roy. Statist. Society 34(2), 87–220 (1972).
- 13 . Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53(282), 457–481 (1958).
- 14 . Radio-frequency ablation of colorectal liver metastases in 167 patients. Eur. Radiol. 14(12), 2261–2267 (2004).
- 15 Stereotactic body radiotherapy (SBRT) with or without surgery for primary and metastatic liver tumors. HPB (Oxford) 18(1), 88–97 (2016).
- 16 . Survival after hepatic resection for colorectal metastases: a 10-year experience. Ann. Surg. Oncol. 13(5), 668–676 (2006).
- 17 . Radiofrequency ablation permits an effective treatment for colorectal liver metastasis. Eur. J. Surg. Oncol. 33(1), 67–71 (2007).
- 18 Stereotactic body radiation therapy in primary and metastatic liver disease. Anticancer Res. 37(12), 7005–7010 (2017).
- 19 The impact of pulmonary metastasectomy in patients with previously resected colorectal cancer liver metastases. PLoS ONE 12(3), e0173933 (2017).
- 20 . Survival after pulmonary metastasectomy in colorectal cancer patients: does a history of resected liver metastases worsen the prognosis? A literature review. Cancer Biol. Med. 14(3), 281–286 (2017).
- 21 Multi-institutional Phase I/II trial of stereotactic body radiation therapy for lung metastases. J. Clin. Oncol. 27(10), 1579–1584 (2009).
- 22 . Descriptive analysis of oligometastatic lesions treated with curative-intent stereotactic body radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 72(5), 1516–1522 (2008).
